Tarsus Pharmaceuticals (TARS) EBIT Margin (2021 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly EBIT Margin of 3.78% for Q1 2026, up 2977.0% year-over-year from 0.12% in Q1 2025, and up 28.16% quarter-over-quarter from 5.26% in Q4 2025.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) EBIT Margin (2021 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' EBIT Margin history runs 6 years deep, the most recent figure standing at 3.78% for Q1 2026.
- In Q1 2026, EBIT Margin rose 2977.0% year-over-year to 3.78%; the TTM figure through Mar 2026 stood at 9.5% (up 3722.0% YoY), while the FY2025 annual figure was 15.72%, up 5018.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 3.78%, up from 5.26% in the prior quarter.
- The five-year high for EBIT Margin was 3.78% in Q1 2026, with the low at 3621.71% in Q1 2022.
- The 5-year median for EBIT Margin is 52.29% (2024), against an average of 514.4%.
- Peak annual rise in EBIT Margin reached 412395 bps in 2022, while the deepest fall reached 365375 bps in 2022.
- Tarsus Pharmaceuticals' EBIT Margin stood at 150.61% in 2022, then slumped by 126 bps to 339.94% in 2023, then jumped by 89 bps to 36.77% in 2024, then soared by 86 bps to 5.26% in 2025, then climbed by 28 bps to 3.78% in 2026.
- Business Quant data shows TARS's EBIT Margin at 3.78% in Q1 2026, 5.26% in Q4 2025, and 12.24% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | -11.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.45% |
| Mar 31, 2026 | -3.78% |
| Dec 31, 2025 | -5.26% |
| Sep 30, 2025 | -12.24% |
| Jun 30, 2025 | -21.61% |
| Mar 31, 2025 | -33.55% |
| Dec 31, 2024 | -36.77% |
| Sep 30, 2024 | -52.29% |
| Jun 30, 2024 | -81.60% |
| Mar 31, 2024 | -136.47% |
| Dec 31, 2023 | -339.94% |
| Sep 30, 2023 | -2,187.87% |
| Mar 31, 2023 | -998.08% |
| Dec 31, 2022 | -150.61% |
| Jun 30, 2022 | -34.20% |
| Mar 31, 2022 | -3,621.71% |
| Dec 31, 2021 | -4,274.56% |
| Sep 30, 2021 | -1,266.53% |
| Jun 30, 2021 | 33.07% |
| Mar 31, 2021 | 32.05% |